Pfizer to seek FDA approval for Lyme vaccine
Digest more
Up until recently, the stock has been a chronic underperformer.
Pfizer and France's Valneva said on Monday their experimental Lyme disease vaccine showed more than 70% efficacy in a ...
Pfizer’s CDK4 inhibitor, atirmociclib, is already being investigated in a Phase III trial as a first-line therapy.
Pfizer has reached a turning point.
March 17 () - Pfizer said on Tuesday its experimental combination reduced the risk of disease progression or death by 40% in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results